» Articles » PMID: 26703429

Uric Acid in Metabolic Syndrome: From an Innocent Bystander to a Central Player

Overview
Specialty General Medicine
Date 2015 Dec 26
PMID 26703429
Citations 141
Authors
Affiliations
Soon will be listed here.
Abstract

Uric acid, once viewed as an inert metabolic end-product of purine metabolism, has been recently incriminated in a number of chronic disease states, including hypertension, metabolic syndrome, diabetes, non-alcoholic fatty liver disease, and chronic kidney disease. Several experimental and clinical studies support a role for uric acid as a contributory causal factor in these conditions. Here we discuss some of the major mechanisms linking uric acid to metabolic and cardiovascular diseases. At this time the key to understanding the importance of uric acid in these diseases will be the conduct of large clinical trials in which the effect of lowering uric acid on hard clinical outcomes is assessed. Elevated uric acid may turn out to be one of the more important remediable risk factors for metabolic and cardiovascular diseases.

Citing Articles

Correlation of the lipid complex marker hs-CRP/HDL-C ratio with hyperuricaemia: a cross-sectional retrospective study from NHANES 2015-2018.

Jinfeng W, Jinhao G, Xianglin Y, Hongbin Q, Jiarui Z Sci Rep. 2025; 15(1):8495.

PMID: 40075070 PMC: 11903692. DOI: 10.1038/s41598-024-83126-8.


Risk factors and prediction model of metabolic disorders in adult patients with pituitary stalk interruption syndrome.

Jiang D, Wang S, Xiao Y, Zhi P, Zheng E, Lyu Z Sci Rep. 2025; 15(1):7740.

PMID: 40044792 PMC: 11882961. DOI: 10.1038/s41598-025-91461-7.


Serum uric acid as a biomarker for metabolic dysfunction-associated steatotic liver disease: insights from ultrasound elastography in a Chinese cohort.

Chang Z, Liu Z BMC Gastroenterol. 2025; 25(1):94.

PMID: 39979872 PMC: 11841239. DOI: 10.1186/s12876-025-03666-9.


Biohybrid Nanosystem Fabricated with Marine Diatom for Uric Acid Detection.

Yang X, Long S, Wang B, Chen J, Xiong Y, Ying M ACS Biomater Sci Eng. 2025; 11(3):1792-1805.

PMID: 39967329 PMC: 11897952. DOI: 10.1021/acsbiomaterials.4c02312.


Analysis of the Efficacy of Different Obesity Surgeries in Patients with Metabolic Syndrome.

Qi T, Ding Y, Dai X, He J, Zhang H, Wu L Obes Surg. 2025; 35(3):763-774.

PMID: 39798048 DOI: 10.1007/s11695-025-07673-3.


References
1.
Kim H, Seo Y, Song Y . Four-week effects of allopurinol and febuxostat treatments on blood pressure and serum creatinine level in gouty men. J Korean Med Sci. 2014; 29(8):1077-81. PMC: 4129198. DOI: 10.3346/jkms.2014.29.8.1077. View

2.
Masuo K, Kawaguchi H, Mikami H, Ogihara T, Tuck M . Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003; 42(4):474-80. DOI: 10.1161/01.HYP.0000091371.53502.D3. View

3.
Chao H, Liu J, Lin J, Chen C, Wu C, Cheng T . Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. Acta Pharmacol Sin. 2008; 29(11):1301-12. DOI: 10.1111/j.1745-7254.2008.00877.x. View

4.
Lanaspa M, Ishimoto T, Li N, Cicerchi C, Orlicky D, Ruzycki P . Endogenous fructose production and metabolism in the liver contributes to the development of metabolic syndrome. Nat Commun. 2013; 4:2434. PMC: 3833672. DOI: 10.1038/ncomms3434. View

5.
Ogino K, Kato M, Furuse Y, Kinugasa Y, Ishida K, Osaki S . Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2009; 3(1):73-81. DOI: 10.1161/CIRCHEARTFAILURE.109.868604. View